Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Immunomedics (IMMU) today and set a price target of $30. The company’s shares opened today at $11.87, close to its 52-week low of $11.55.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.5% and a 48.2% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Immunomedics is a Strong Buy with an average price target of $29.67, a 150.0% upside from current levels. In a report released today, Jefferies also maintained a Buy rating on the stock with a $21 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.33 and a one-year low of $11.55. Currently, Immunomedics has an average volume of 2.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments.
